# 24h

150

#### 100

150

#### 100

D

MiaPaCa2

GI50 = 939.1 g/mL

\*

\*\*

#### 50 50

A

HPDE

\*\* GI50 = 516.5 g/mL

\*\*\*\*

\*\*\*\*

\*\*\*\*

% Viability

% Viability

0 0

48h

150

Dose F3 (g/mL)

#### 150

B

GI50= 942.6 g/mL

\*\*\*

\*\*\*\*

\*\*\*\*

\*\*\*\*

Dose F3 (g/mL)

#### 100 100

E

\*\*\*\* \*\*\*\*

\*\*\*\*

% Viability

% Viability

50 50

0 0

72h

150

Dose F3 (g/mL)

#### 150

Dose F3 (µg/mL)

#### 100 100

C

\*

GI50 = 857.1 g/mL

\*\*\* \*\*\*\* \*\*\*\*

\*\*\*\*

\*\*\*\*

\*\*\*\*

F

\*\*\*\*

% Viability

% Viability

50 50

0 0

Dose F3 (g/mL)

Supplementary Figure 4 Viability of HPDE and MiaPaCa2 cells treated with Fraction 3 (F3) ranging from 0-1000 µg/mL and Gemcitabine 50nM as determined by CCK8 colourimetric assay. *HPDE cells treated with F3 for A: 24 hours (GI50 516.5 µg/mL), B: 48 hours (GI50 942.6 µg/mL), C: 72 hours (GI50 857.1 µg/mL), MiaPaCa2 cells treated with F3 for D: 24 hours (GI50 939.1 µg/mL) E: 48 hours, F: 72 hours. Significance between treatment groups and the negative control calculated using one-way ANOVA represented over treatment columns by ‘\*’ = p<0.05, ‘\*\*’ = p<0.01, ‘\*\*\*’ = p<0.005, ‘\*\*\*\*’ = p<0.001.*

Dose F3 (g/mL)